HGH Fragment 176-191 5mg
A truncated C-terminal human growth hormone peptide investigated in laboratory settings for lipolytic signaling without glycemic perturbation.
Mechanism
Stimulates hormone-sensitive lipase and inhibits acetyl-CoA carboxylase within adipocytes to drive triglyceride hydrolysis without altering serum glucose or IGF-1.
Dosing
Standard laboratory conventions document a starting subcutaneous protocol of 250 mcg once or twice daily while fasted.
Reconstitution
Mix with 2 mL bacteriostatic water to achieve a final working concentration of 2.5 mg/mL.
Storage
Store the reconstituted solution refrigerated at 2 to 8 degrees Celsius protected from light, avoiding freezing and rough agitation.
Mix & measure HGH Fragment 176-191 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure HGH Fragment 176-191 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 20.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Initial / Starting | 250 mcg (Once or twice daily, fasted) | 10 units (0.10 mL) |
| Intermediate | 300 mcg (Once or twice daily, fasted) | 12 units (0.12 mL) |
| Moderate | 400 mcg (Once or twice daily, fasted) | 16 units (0.16 mL) |
| Upper Range | 500 mcg (Once or twice daily, fasted) | 20 units (0.20 mL) |
Reconstitution Steps
- 1
Disinfect the rubber stoppers of both the peptide vial and the bacteriostatic water container with fresh alcohol swabs.
- 2
Draw 2 mL of bacteriostatic water into a sterile mixing syringe.
- 3
Insert the needle and trickle the diluent slowly down the glass wall of the vial to prevent clumping of the delicate peptide powder.
- 4
Permit the vial to rest briefly, then gently roll or swirl between your hands until completely dissolved without shaking.
- 5
Visually verify that the solution is transparent and free of precipitates before transferring to refrigerated storage at 2 to 8 °C.
Supplies Needed
Peptide Vial
Lyophilized research vial containing 5 mg of purified HGH Fragment 176-191.
Insulin Syringes (U-100)
Precision measuring instruments calibrated with 100 units per mL for precise microgram draws.
Bacteriostatic Water
Sterile diluent preserved with 0.9% benzyl alcohol used to reconstitute 2 mL per vial.
Alcohol Swabs
Sterile isopropyl alcohol pads used to decontaminate rubber stoppers prior to puncturing.
Why researchers study it
Differential pharmacology versus the modified analog AOD-9604
Preclinical adipose tissue lipolysis and hormone-sensitive lipase induction
Absence of IGF-1 mediated growth effects and glycemic impairment
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
HGH Fragment 176-191 represents an isolated 16-amino-acid synthetic domain corresponding to the carboxyl terminus of native human somatotropin. Originally isolated during basic endocrinology research attempting to untangle growth stimulation from metabolic effects, this peptide models the isolated fat-clearing action of growth hormone without activating systemic IGF-1 signaling cascades. Laboratory models examine this truncated peptide for its capacity to stimulate lipid mobilization and reduce adipocyte volume without the diabetogenic outcomes, fluid retention, or insulin resistance typically seen with whole-chain human growth hormone administration. While it exhibits robust lipolytic activity in rodent trials, its physiological distinction from the modified variant AOD-9604 remains a critical factor in comparative peptide research. Because this peptide lacks regulatory approval for human clinical therapy, literature values are derived primarily from preclinical animal work and published grey-market benchmarks. Research environments utilize these standardized guidelines to ensure accurate reconstitution, measurement, and experimental handling.
References
- 1.Ng et al., Journal of Molecular Endocrinology, 2000 — C-terminal hGH domain (residues 177-191) lipolytic actions without diabetogenic effects in Zucker rats
- 2.Heffernan et al., Endocrinology, 2001 — Lipid metabolism and beta-3 adrenergic receptor involvement of hGH and lipolytic fragments in obese mice
- 3.Wilding, Current Opinion in Investigational Drugs, 2004 — Clinical overview of the related modified analog AOD-9604 in obesity trials
- 4.Cox et al., Drug Testing and Analysis, 2014 — Structural definition, sports prohibition, and analytical urine detection of AOD9604
- 5.Orlovius et al., Drug Testing and Analysis, 2013 — Doping analysis and interaction of hGH C-terminal fragments with isoform immunoassay
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allIpamorelin 5mg
Selective pentapeptide GH secretagogue acting on the GHS-R1a receptor to trigger somatotropic release without elevating cortisol or prolactin.
View ProtocolMOTS-c 10mg
Mitochondrial-derived 16-amino acid peptide that activates AMPK and regulates cellular energy metabolism and insulin sensitivity.
View ProtocolTesofensine 0.5mg
An investigational oral triple monoamine reuptake inhibitor researched in Phase II clinical trials for weight regulation and appetite suppression.
View Protocol